A startup spun out of Stanford, Aza Technology is described as poised to deliver point-of-care device targeting diagnosis and management of hyperammonemia - responsible for a host of neurotoxic effects seen in Urea Cycle Disorder (UCD) and organic acidemia (OA) patients. Hyperammonemia is also referenced as a root cause of hepatic encephalopathy - a serious condition secondary only to alcoholic and non-alcoholic cirrhosis (NASH), resulting in over $2 billion in hospitalizations in the US alone. The foundational intellectual property under development at Aza Technology is described as enabling a home-use and point-of-care diagnostic device for evaluation of blood ammonia levels. In concert with their physicians, end-users would have capability to treat their own ammonia elevations with their choice of several safe and effective therapeutics.
